The NF-κB activation pathways, emerging molecular targets for cancer prevention and therapy

Importance of the field: Nuclear factor kappa B (NF-κB) is activated by a variety of cancer-promoting agents. The reciprocal activation between NF-κB and inflammatory cytokines makes NF-κB important for inflammation-associated cancer development. Both the constitutive and anticancer therapeutic-induced NF-κB activation blunts the anticancer activities of the therapy. Elucidating the roles of NF-κB in cancer facilitates developing approaches for cancer prevention and therapy. Areas covered in this review: By searching PubMed, we summarize the progress of studies on NF-κB in carcinogenesis and cancer cells' drug resistance in recent 10 years. What the reader will gain: The mechanisms by which NF-κB activation pathways are activated; the roles and mechanisms of NF-κB in cell survival and proliferation, and in carcinogenesis and cancer cells' response to therapy; recent development of NF-κB-modulating means and their application in cancer prevention and therapy. Take home message: NF-κB is involved in cancer development, modulating NF-κB activation pathways has important implications in cancer prevention and therapy. Due to the complexity of NF-κB roles in different cancers, careful evaluation of NF-κB's in each cancer type is crucial in this regard. More cancer cell-specific NF-κB inhibiting means are desired for improving anticancer efficacy and reducing systemic toxicity.

[1]  B. Aggarwal,et al.  Nuclear Factor-κB Activation: From Bench to Bedside , 2008 .

[2]  Pei-Ming Yang,et al.  Loss of IKKβ activity increases p53 stability and p21 expression leading to cell cycle arrest and apoptosis , 2009, Journal of cellular and molecular medicine.

[3]  S. Belinsky,et al.  A Critical Role of Luteolin-Induced Reactive Oxygen Species in Blockage of Tumor Necrosis Factor-Activated Nuclear Factor-κB Pathway and Sensitization of Apoptosis in Lung Cancer Cells , 2007, Molecular Pharmacology.

[4]  Alexander A. Shishkin,et al.  Targeting transcription factor NFκB: comparative analysis of proteasome and IKK inhibitors , 2009, Cell cycle.

[5]  J. Tschopp,et al.  Signals from within: the DNA-damage-induced NF-κB response , 2006, Cell Death and Differentiation.

[6]  Fang Wang,et al.  Proteasome Inhibition Activates Epidermal Growth Factor Receptor (EGFR) and EGFR-Independent Mitogenic Kinase Signaling Pathways in Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[7]  J. Tschopp,et al.  PIDD Mediates NF-κB Activation in Response to DNA Damage , 2005, Cell.

[8]  N. Fusenig,et al.  Critical role for NF‐κB‐induced JunB in VEGF regulation and tumor angiogenesis , 2007 .

[9]  J. Borowitz,et al.  NF‐κB‐mediated up‐regulation of Bcl‐XS and Bax contributes to cytochrome c release in cyanide‐induced apoptosis , 2002, Journal of neurochemistry.

[10]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[11]  Hong Tang,et al.  IKKβ-mediated nuclear factor-κB activation attenuates smac mimetic–induced apoptosis in cancer cells , 2009, Molecular Cancer Therapeutics.

[12]  J. Baron.  Aspirin and NSAIDs for the prevention of colorectal cancer. , 2009, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[13]  C. Sotiriou,et al.  Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner , 2006, Molecular Cancer Therapeutics.

[14]  C. Schindler,et al.  NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. , 2006, The Journal of clinical investigation.

[15]  Hua Liu,et al.  A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[16]  S. Jee,et al.  Stromal cell-derived factor-1alpha (SDF-1alpha/CXCL12)-enhanced angiogenesis of human basal cell carcinoma cells involves ERK1/2-NF-kappaB/interleukin-6 pathway. , 2009, Carcinogenesis.

[17]  Wenshu Chen,et al.  Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-kappaB and Akt pathways. , 2007, Biochemical and biophysical research communications.

[18]  Vishva M. Dixit,et al.  IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis , 2007, Cell.

[19]  Han-Ming Shen,et al.  NFκB signaling in carcinogenesis and as a potential molecular target for cancer therapy , 2009, Apoptosis.

[20]  É. Álvarez,et al.  Inhibition of NF-κB activity by BAY 11-7082 increases apoptosis in multidrug resistant leukemic T-cell lines , 2005 .

[21]  J. Arbiser,et al.  Curcumin as an inhibitor of angiogenesis. , 2007, Advances in experimental medicine and biology.

[22]  上塚 大一.  Inhibition of inducible NF-κB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line , 2003 .

[23]  S. Yamaoka,et al.  Activation of NF-κB by HTLV-I and implications for cell transformation , 2005, Oncogene.

[24]  J. Schmid,et al.  BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways , 2006, Clinical Cancer Research.

[25]  A. Hoffmann,et al.  CK2 Is a C-Terminal IκB Kinase Responsible for NF-κB Activation during the UV Response , 2003 .

[26]  S. Belinsky,et al.  17-allylamino-17-demethoxygeldanamycin synergistically potentiates tumor necrosis factor-induced lung cancer cell death by blocking the nuclear factor-kappaB pathway. , 2006, Cancer research.

[27]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[28]  A. Griffioen,et al.  A new role for NF-κB in angiogenesis inhibition , 2007, Cell Death and Differentiation.

[29]  Dong-Hyun Kim,et al.  A ginseng saponin metabolite suppresses tumor necrosis factor-α-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells , 2008 .

[30]  Chris Twelves,et al.  Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. , 2005, European journal of cancer.

[31]  D. Lane,et al.  Updates on p53: modulation of p53 degradation as a therapeutic approach , 2008, British Journal of Cancer.

[32]  W. Fairbrother,et al.  c-IAP1 and c-IAP2 Are Critical Mediators of Tumor Necrosis Factor α (TNFα)-induced NF-κB Activation* , 2008, Journal of Biological Chemistry.

[33]  M. Manns,et al.  Induction of Mdr1b expression by tumor necrosis factor‐α in rat liver cells is independent of p53 but requires NF‐κB signaling , 2001 .

[34]  Yong Lin,et al.  Tumor necrosis factor and cancer, buddies or foes? , 2008, Acta Pharmacologica Sinica.

[35]  G. Haegeman,et al.  Recruitment of IκBα to the hes1 promoter is associated with transcriptional repression , 2004 .

[36]  G. Wahl,et al.  p53 stabilization is decreased upon NFkappaB activation: a role for NFkappaB in acquisition of resistance to chemotherapy. , 2002, Cancer cell.

[37]  Zhijian J. Chen.  Ubiquitin signalling in the NF-κB pathway , 2005, Nature Cell Biology.

[38]  K. Anderson,et al.  Emerging Therapies for Multiple Myeloma , 2006, Expert opinion on emerging drugs.

[39]  S. Srinivasula,et al.  Sensing of Lys 63-linked polyubiquitination by NEMO is a key event in NF-κB activation , 2006, Nature Cell Biology.

[40]  M. Nagarkatti,et al.  Role of Dioxin Response Element and Nuclear Factor-κB Motifs in 2,3,7,8-Tetrachlorodibenzo-p-dioxin-Mediated Regulation of Fas and Fas Ligand Expression , 2006, Molecular Pharmacology.

[41]  S. Kaneko,et al.  Molecular functions and biological roles of hepatitis B virus x protein , 2006, Cancer science.

[42]  Yiwei Li,et al.  NF-kappaB: a potential target for cancer chemoprevention and therapy. , 2008, Frontiers in bioscience : a journal and virtual library.

[43]  Jian Yu,et al.  PUMA is directly activated by NF-κB and contributes to TNF-α-induced apoptosis , 2009, Cell Death and Differentiation.

[44]  Katerina Akassoglou,et al.  NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α , 2008, Nature.

[45]  D. Dreyfus,et al.  Modulation of p53 activity by IκBα: Evidence suggesting a common phylogeny between NF-κB and p53 transcription factors , 2005, BMC Immunology.

[46]  P. Vandenabeele,et al.  RIP1, a kinase on the crossroads of a cell's decision to live or die , 2007, Cell Death and Differentiation.

[47]  Michael Karin,et al.  Is NF-κB a good target for cancer therapy? Hopes and pitfalls , 2009, Nature Reviews Drug Discovery.

[48]  B. Aggarwal,et al.  Nuclear factor-kappaB: the enemy within. , 2004, Cancer cell.

[49]  O. Fardel,et al.  Interleukin-8 induction by the environmental contaminant benzo(a)pyrene is aryl hydrocarbon receptor-dependent and leads to lung inflammation. , 2008, Toxicology letters.

[50]  B. Aggarwal,et al.  Cigarette smoke condensate activates nuclear transcription factor-κB through phosphorylation and degradation of IκBα: correlation with induction of cyclooxygenase-2 , 2002 .

[51]  M. Karin.  Nuclear factor-κB in cancer development and progression , 2006, Nature.

[52]  Gabriel Pineda,et al.  Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. , 2006, Molecular cell.

[53]  W. Liao,et al.  The essential role of MEKK3 in TNF-induced NF-κB activation , 2001, Nature Immunology.

[54]  R. Gaynor,et al.  Constitutive activation of NF-κB in Ki-ras-transformed prostate epithelial cells , 2002, Oncogene.

[55]  M. Kelliher,et al.  The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. , 2000, Immunity.

[56]  L. Neckers,et al.  Disruption of Hsp90 Function Results in Degradation of the Death Domain Kinase, Receptor-interacting Protein (RIP), and Blockage of Tumor Necrosis Factor-induced Nuclear Factor-κB Activation* , 2000, The Journal of Biological Chemistry.

[57]  M. Tabata,et al.  Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. , 2002, Current pharmaceutical design.

[58]  Young Yang,et al.  Suppression of NF-kappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells. , 2009, Carcinogenesis.

[59]  T. Mak,et al.  Bcl10 Is a Positive Regulator of Antigen Receptor–Induced Activation of NF-κ B and Neural Tube Closure , 2001, Cell.

[60]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[61]  Michael Karin,et al.  IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer , 2004, Cell.

[62]  B. Aggarwal.  Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[63]  P. Hammerman,et al.  Lymphocyte Transformation by Pim-2 Is Dependent on Nuclear Factor-κB Activation , 2004, Cancer Research.

[64]  Wenshu Chen,et al.  Blockage of NF‐κB by IKKβ‐ or RelA‐siRNA rather than the NF‐κB super‐suppressor IκBα mutant potentiates adriamycin‐induced cytotoxicity in lung cancer cells , 2008, Journal of cellular biochemistry.

[65]  B. Marinari,et al.  RelA/NF-κB recruitment on the bax gene promoter antagonizes p73-dependent apoptosis in costimulated T cells , 2008, Cell Death and Differentiation.

[66]  M. Karin,et al.  Inhibition of JNK activation through NF-κB target genes , 2001, Nature.

[67]  Jian Jian Li,et al.  ATM-NF-κB Connection as a Target for Tumor Radiosensitization , 2007 .

[68]  G. Sonenshein,et al.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2 , 2007, Nature Cell Biology.

[69]  Irfan Rahman,et al.  Regulation of inflammation and redox signaling by dietary polyphenols. , 2006, Biochemical pharmacology.

[70]  David L. Vaux,et al.  IAP Antagonists Target cIAP1 to Induce TNFα-Dependent Apoptosis , 2007, Cell.

[71]  L. Neckers,et al.  Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics – an update , 2005, Expert opinion on emerging drugs.

[72]  Howard Y. Chang,et al.  Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. , 2009, Cancer cell.

[73]  M. Merville,et al.  Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation , 2005 .

[74]  David F. Kashatus,et al.  The Nuclear Factor κB Subunits RelA/p65 and c-Rel Potentiate but Are Not Required for Ras-Induced Cellular Transformation , 2004, Cancer Research.

[75]  H. Beug,et al.  Epithelial-Mesenchymal Transition: NF-κB Takes Center Stage , 2004 .

[76]  S. Han,et al.  The effect of adenovirus-IkappaBalpha transduction on the chemosensitivity of lung cancer cell line with resistance to cis-diamminedichloroplatinum(II)(cisplatin) and doxorubicin(adriamycin). , 2003, Lung cancer.

[77]  A. Protopopov,et al.  Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. , 2009, Blood.

[78]  H. Adami,et al.  Infections as a major preventable cause of human cancer , 2000, Journal of internal medicine.

[79]  I. Verma,et al.  IκB Kinase-Independent IκBα Degradation Pathway: Functional NF-κB Activity and Implications for Cancer Therapy , 2003, Molecular and Cellular Biology.

[80]  W. Woods,et al.  Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53 , 2003, Oncogene.

[81]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[82]  G. Wahl,et al.  p53 stabilization is decreased upon NFκB activation , 2002 .

[83]  S. Miyamoto,et al.  PIDD: A Switch Hitter , 2005, Cell.

[84]  Jian Yu,et al.  NSAIDs Downregulate Bcl-XL and Dissociate BAX and Bcl-XL to Induce Apoptosis in Colon Cancer Cells , 2008, Nutrition and cancer.

[85]  Michael Karin,et al.  Reactive Oxygen Species Promote TNFα-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases , 2005, Cell.

[86]  S. Jee,et al.  Stromal cell-derived factor-1 a ( SDF-1 a / CXCL 12 )-enhanced angiogenesis of human basal cell carcinoma cells involves ERK 1 / 2 – NFk B / interleukin-6 pathway , 2009 .

[87]  V. Castranova,et al.  Nuclear Factor-κB, an Unappreciated Tumor Suppressor: Figure 1. , 2007 .

[88]  N. Perkins,et al.  NF-κB: tumor promoter or suppressor? , 2004 .

[89]  Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. , 2006, Cancer research.

[90]  K. Vousden,et al.  Role of NF-κB in p53-mediated programmed cell death , 2000, Nature.

[91]  S. Katiyar,et al.  Multi-targeted prevention and therapy of cancer by proanthocyanidins. , 2008, Cancer letters.

[92]  V. Castranova,et al.  Nuclear factor-kappaB, an unappreciated tumor suppressor. , 2007, Cancer research.

[93]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[94]  M. Omata,et al.  Constitutive NF-κB Activation in Colorectal Carcinoma Plays a Key Role in Angiogenesis, Promoting Tumor Growth , 2009, Clinical Cancer Research.

[95]  Xiaodong Wang,et al.  TNF-α Induces Two Distinct Caspase-8 Activation Pathways , 2008, Cell.

[96]  E. Zandi,et al.  Tumor Necrosis Factor α-dependent Drug Resistance to Purine and Pyrimidine Analogues in Human Colon Tumor Cells Mediated through IKK* , 2005, Journal of Biological Chemistry.

[97]  Sankar Ghosh,et al.  Signaling to NF-kappaB. , 2004, Genes & development.

[98]  P. Debré,et al.  Constitutive activation of NF-kB in human thymocytes. , 1991, Biochemical and biophysical research communications.

[99]  D. Seldin,et al.  Protein Kinase CK2 Promotes Aberrant Activation of Nuclear Factor-κB, Transformed Phenotype, and Survival of Breast Cancer Cells , 2002 .

[100]  N. Perkins,et al.  Active Repression of Antiapoptotic Gene Expression by RelA(p65) NF-κB , 2004 .

[101]  Yong Lin,et al.  Luteolin, a flavonoid with potential for cancer prevention and therapy. , 2008, Current cancer drug targets.

[102]  T. Mak,et al.  Activation of noncanonical NF-κB requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2, TRAF3 and the kinase NIK , 2008, Nature Immunology.

[103]  H. Nakano,et al.  The death domain kinase RIP has an essential role in DNA damage-induced NF-kappa B activation. , 2003, Genes & development.

[104]  Y. Kaneda,et al.  Inhibition of inducible NF-kappaB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. , 2003, Experimental cell research.

[105]  B. Aggarwal,et al.  Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term Foe , 2009, Clinical Cancer Research.